Challenging Environment For Biopharma Is A Tailwind For Royalty Pharma
How did your country report this? Share your view in the comments.
Diverging Reports Breakdown
Challenging Environment For Biopharma Is A Tailwind For Royalty Pharma
The royalty revenue stream acquirer has around 40 products in its portfolio. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.
Read full article ▼
The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.
Source: Insights.citeline.com | View original article
Source: https://insights.citeline.com//scrip/business/deals/challenging-environment-for-biopharma-is-a-tailwind-for-royalty-pharma-Q6UYTDAZXFEADOK7YU5MJAEZBE/